Saudi Med J
-
To evaluate the effectiveness and safety of rivaroxaban anticoagulation in COVID-19 patients. ⋯ Rivaroxaban may reduce thrombotic events in COVID-19 patients, but it does not appear to have an advantage over heparin or LMWH, and it may increase the risk of bleeding.INPLASY Reg. No.: INPLASY 202370097.